Glen S. Germain

Imatinib Mesylate Is a Potent Inhibitor of the ABCG2 (BCRP) Transporter and Reverses Resistance to Topotecan and SN-38 <b> <i>in Vitro</i> </b>

Peter J. Houghton, Glen S. Germain, Franklin C. Harwood et al. · Cancer Research · 2004 · 322 citations · Full text

Medicine, Oncology, Pharmacology +15

Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells.

Hajime Hosoi, Michael B. Dilling, Takuma Shikata et al. · PubMed · 1999 · 316 citations

Medicine, Oncology, Pharmacology +17

Gefitinib Enhances the Antitumor Activity and Oral Bioavailability of Irinotecan in Mice

Clinton F. Stewart, Markos Leggas, John D. Schuetz et al. · Cancer Research · 2004 · 201 citations

Medicine, Pharmacokinetics, Pharmacology +15

Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor.

Michael B. Dilling, Peter Dias, David N. Shapiro et al. · PubMed · 1994 · 135 citations

Medicine, Oncology, Pharmacology +17

Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft.

H. S. Friedman, S P Johnson, Qing Dong et al. · PubMed · 1997 · 133 citations

Medicine, Cancer Biology, Pharmacology +16